Moeen Khan

Array ( [id] => 11499222 [patent_doc_number] => 20170073406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION' [patent_app_type] => utility [patent_app_number] => 15/309141 [patent_app_country] => US [patent_app_date] => 2015-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 89171 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15309141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16305365 [patent_doc_number] => 10774143 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-09-15 [patent_title] => Modulation of T cell signaling via slat association with IP3R1 [patent_app_type] => utility [patent_app_number] => 14/702059 [patent_app_country] => US [patent_app_date] => 2015-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 37 [patent_no_of_words] => 22354 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14702059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12569166 [patent_doc_number] => 10018636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Method for diagnosing fibromyalgia [patent_app_type] => utility [patent_app_number] => 14/692338 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7000 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14692338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10470179 [patent_doc_number] => 20150355195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-10 [patent_title] => 'METHODS FOR PREDICTING AND MONITORING MUCOSAL HEALING' [patent_app_type] => utility [patent_app_number] => 14/678455 [patent_app_country] => US [patent_app_date] => 2015-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 74357 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14678455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12022235 [patent_doc_number] => 20170312334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/301583 [patent_app_country] => US [patent_app_date] => 2015-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 42012 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15301583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649167 [patent_doc_number] => 20170145068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'NOVEL IFN BETA PROTEIN ANALOGS' [patent_app_type] => utility [patent_app_number] => 15/300288 [patent_app_country] => US [patent_app_date] => 2015-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 4646 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15300288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11210930 [patent_doc_number] => 09439947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-13 [patent_title] => 'Therapy for radiation-induced lung injury' [patent_app_type] => utility [patent_app_number] => 14/666746 [patent_app_country] => US [patent_app_date] => 2015-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 2722 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14666746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10306540 [patent_doc_number] => 20150191540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'PREVENTIVE OR THERAPEUTIC AGENT FOR SENSITIZED T CELL-MEDIATED DISEASES COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT' [patent_app_type] => utility [patent_app_number] => 14/662139 [patent_app_country] => US [patent_app_date] => 2015-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10816 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14662139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834682 [patent_doc_number] => 20170216401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'COMBINATION FOR USE IN A METHOD OF TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/126687 [patent_app_country] => US [patent_app_date] => 2015-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8603 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15126687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10297633 [patent_doc_number] => 20150182632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-02 [patent_title] => 'ANTI-INTERLEUKIN-1 (IL-1) ANTIBODY USED AS A TARGETING AGENT TO TREAT ARTHRITIS AND OTHER DISEASES' [patent_app_type] => utility [patent_app_number] => 14/656222 [patent_app_country] => US [patent_app_date] => 2015-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6359 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14656222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333636 [patent_doc_number] => 20150218641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'METHOD FOR PROGNOSTICATING THE CLINICAL RESPONSE OF A PATIENT TO B-LYMPHOCYTE INHIBITING OR DEPLETING THERAPY IN INTERFERON-DRIVEN DISEASES SUCH AS SLE' [patent_app_type] => utility [patent_app_number] => 14/634529 [patent_app_country] => US [patent_app_date] => 2015-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 22017 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14634529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340478 [patent_doc_number] => 20150225483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'TARGETED TGFß INHIBITION' [patent_app_type] => utility [patent_app_number] => 14/618454 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 22872 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14618454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10254954 [patent_doc_number] => 20150139951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-21 [patent_title] => 'ENGINEERED ANTIBODY-INTERFERON MUTANT FUSION MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/611945 [patent_app_country] => US [patent_app_date] => 2015-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 16865 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14611945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13237031 [patent_doc_number] => 10131707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-20 [patent_title] => Treatment of sepsis and septic shock [patent_app_type] => utility [patent_app_number] => 15/106550 [patent_app_country] => US [patent_app_date] => 2015-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 17493 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15106550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11415288 [patent_doc_number] => 09562105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-07 [patent_title] => 'Human monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 14/603001 [patent_app_country] => US [patent_app_date] => 2015-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33191 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114906 [patent_doc_number] => 20160311879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'SINGLE CHAIN IL-12 NUCLEIC ACIDS, POLYPEPTIDES, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/105435 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 27160 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15105435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10202085 [patent_doc_number] => 20150087074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'DIAGNOSTIC ORAL DEVICE' [patent_app_type] => utility [patent_app_number] => 14/569179 [patent_app_country] => US [patent_app_date] => 2014-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2227 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14569179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11330941 [patent_doc_number] => 09522174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-20 [patent_title] => 'Stable liquid interferon beta formulations' [patent_app_type] => utility [patent_app_number] => 14/564637 [patent_app_country] => US [patent_app_date] => 2014-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11780 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14564637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10297593 [patent_doc_number] => 20150182592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-02 [patent_title] => 'Composition Comprising At Least Two Compounds Which Induce Indolamine 2,3 - Dioxygenase (IDO), for the Treatment of an Autoimmune Disorder or Suffering from Immune Rejection of Organs' [patent_app_type] => utility [patent_app_number] => 14/553098 [patent_app_country] => US [patent_app_date] => 2014-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 9907 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14553098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13942483 [patent_doc_number] => 10206986 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Annexin II variant compositions and methods [patent_app_type] => utility [patent_app_number] => 15/036115 [patent_app_country] => US [patent_app_date] => 2014-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 9020 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15036115 [rel_patent_id] =>[rel_patent_doc_number] =>)